Submitted:
26 August 2023
Posted:
30 August 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Limitations of the study
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Konstatinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543-603. [CrossRef]
- Becattini C, Agnelli G, Lankeit M, Masotti L, Pruszczyk P, Casazza F, et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J 2016;48:780-6. [CrossRef]
- Jimenez D, Aujesky D, Lisa Moores L, Gomez V, Lobo L, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383-9. [CrossRef]
- Afzal A, Noor HA, Gill SA, Brawner C, Stein PD. Leukocytosis in Acute Pulmonary Embolism. Chest 1999; 115:1329–32. [CrossRef]
- Huang C-M, Lin Y-C, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, et al. Risk stratification and clinical outcomes in patients with acute pulmonary embolism. Clinical Biochemistry 2011;44:1110–5. [CrossRef]
- Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients Jun Yeon Jo1, Mi Young Lee2, Jin Wook Lee1, Byung Hak Rho3, and Won-Il Choi. BMC Pulmonary Medicine 2013;13:74.
- Xiaowei Zheng X, Zeng N, Wang A, Zhu Z, Zhong C, Xu T, et al. Prognostic value of white blood cell in acute ischemic stroke patients. Curr Neurovasc Res 2018;15(2):151-7.
- Dragu R, Huri S, Zukermann R, Suleiman M, Mutlak D, Agmon Y, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis 2008;196:405-12. [CrossRef]
- Agnello L, Giglio RV, Bivona G, Scazzone C, Gambino CM, Iacona A, et al. The value of a complete blood count (CBC) for sepsis diagnosis and prognosis. Diagnostics 2021;11:1881. [CrossRef]
- Jimenez D, Escobar C, Martí D, Diaz G, Cesar J, Garcia-Avello A, et al. Association of anemia and mortality in patients with acute pulmonary embolism. Thromb Haemost 2009; 102: 153–8.
- Alamin AA. The Role of Red Blood Cells in Hemostasis. Semin Thromb Hemost 2021;47:26-31. [CrossRef]
- Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. New Engl J Med 2014;370:1402-11. [CrossRef]
- Wang Q, MA J, ANG ZJJ, Ming F. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. International Angiology 2018 February;37(1):4-11.
- Kostrubiec M, Łabyk A, Pedowska-Włoszek J, Hrynkiewicz-Szymanska A, Pacho S, Jankowski K, et al, Mean platelet volume predicts early death in acute pulmonary embolism. Heart 2010;96:460-5. [CrossRef]
- Chow W, Wong C, Lau JK, Chow V, Kritharides L, Ng ACC. Impact of persistent anaemia on mortality in patients hospitalized with acute pulmonary embolism: an Australian retrospective observational study. BMJ Open 2019;9:e027112.
- Benshop RJ, Rodriguez-Feurhahn M, Scheldowski M. Catecholamine-induced leukocytosis: early observations, current research, and future directions. Brain Behavior and Immun 1996;10:77-91.
- Nithianandana H, Reillya A, Tritschlera T, Wells P. Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. Thromb Res 2020;195:195–208.




| Survivors N=1448 |
All-cause death N=174 |
PE-related death N=105 |
|
|---|---|---|---|
| Age, y mean±SD Female – n, % COPD – n, % CHF – n, % Malignant dis. – n, % Surgery – n, % Diabetes – n, % Coronary dis. – n, % Stroke – n, % GRF<60ml/min – n, % sPESI>0 – n, % ESC mortality risk Low Intermediate-low Intermediate-high High TLC x109/l median (25th-75th) Hb g/l median (25th-75th) BNP or NT-proBNP (xUNRL) cTn (xUNRL) CRP mg/L (25th-75th) |
63±16 767, 53.0 142, 9.8 195, 13.5 181, 12.5 224, 15.5 274, 18.9 157, 10.9 89, 6.2 474, 33.0 970, 67.0 517, 35.7 372, 25.7 422, 29.1 137, 9.5 10.0 (7.9-12.7) 133 (118-145) 1.86 (0.58-5.85) 2.0 (0.32-9.06) 41.6 (16.1-89.85) |
70±14 94, 55.7 30, 17.2 45, 25.9 36, 20.7 25, 14.4 53, 30.5 31, 18.5 27, 15.6 115, 66.5 159, 91.4 14, 8.0 23, 13.2 69, 39.7 68, 39.1 12.1 (9.3-17.6) 125 (110-141) 6.8 (2.56-17.02) 4.87 (1.57-16.16) 80.50 (44.30-163.6) |
69±15 58, 55.2 13, 12.4 22, 21.0 18, 17.1 14, 13.3 31, 29.5 20, 19.8 17, 16.2 76, 72.4 96, 91.4 5, 4.8 4, 3.8 41, 39.0 55, 52.4 12.4 (9.8-17.6) 123 (107-140) 7.33 (3.52-18.80) 5.06 (2.0-18.3) 78.05 (45.85-164.6) |
| All-cause death | Univariate analysis OR (95%CI, p) |
Multivariate analysis OR (95%CI, p) |
|---|---|---|
| Age Chronic obstructive pulmonary diseaseChronic heart failure Diabetes mellitus type 2 Malignant disease Coronary disease Stroke Chronic renal failure (CrCl<60 ml/min)ESC mortality risk model Intermediate-low Intermediate-high high Total leukocyte count (cut-off 16.5x109/L) Hb (cut-off 125 g/L) |
1.033 (1.021-1.046, <0.001) 1.916 (1.247-2.945, 0.003) 2.242 (1.546-3.250, <0.001) 1.877 (1.324-2.660, <0.001) 1.903 (1.281-2.826, 0.001) 1.858 (1.216-2.838, 0.004) 2.822 (1.776-4.484, <0.001) 4.032 (2.877-5.633, <0.001) - compare to low risk 2.283 (1.159-4.496, 0.017) 6.038 (3.351-10.879, <0.001) 18.330 (10.007-33.575, <0.001) 4.591 (3.160-6.670, <0.001) 1.816 (1.323-2.490, <0.001) |
- - - 1.537 (1.039-2.274, 0.031) - - 2.110 (1.237-3.599, 0.006) 2.549 (1.773-3.665, <0.001) - compare to low risk 2.441 (1.206-4.945, 0.013) 5.506 (2.963-10.229, <0.001) 13.760 (7.239-26.156, <0.001) 3.141 (2.062-4.784, <0.001) 1.775 (1.246-2.530, <0.001) |
| PE-related death | ||
| Age Chronic heart failure Diabetes mellitus type 2 Coronary disease Stroke Chronic renal failure (CrCl<60 ml/min)ESC mortality risk model Intermediate-low Intermediate-high high Total leukocyte count (cut-off 16.5x109/L) Hb (cut-off 125 g/L) |
1.030 (1.014-1.045, <0.001) 1.703 (1.040-2.790, 0.034) 1.795 (1.157-2.785, 0.009) 2.027 (1.209-3.398, 0.007) 2.948 (1.681-5.170, <0.001) 5.330 (3.427-8.290, <0.001) - compare to low risk 1.112 (0.297-4.168, 0.875) 10.046 (3.935-25.648, <0.001) 41.511 (16.302-105.70, <0.001) 4.722 (2.997-7.441, <0.001) 2.108 (1.412-3.1.47, <0.001) |
- - - - 2.091 (1.083-4.035, 0.028) 3.138 (1.940-5.076, <0.001) - compare to low risk 1.112 (0.297-4.239, 0.865) 8.341 (3.233-21.518, <0.001) 29.497 (11.414-76.230, <0.001) 2.738 (1.606-4.667, <0.001) 2.050 (1.301-3.320, 0.002) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).